Platelet-Rich Plasma Promotes the Expansion of Human Myoblasts and Favors the In Vitro Generation of Human Muscle Reserve Cells in a Deeper State of Quiescence.
Axel TollanceAlexandre ProlaDiego MichelAxelle BoucheAntoine TurziDidier HannoucheSarah BerndtThomas LaumonierPublished in: Stem cell reviews and reports (2024)
Stem cell therapy holds significant potential for skeletal muscle repair, with in vitro-generated human muscle reserve cells (MuRCs) emerging as a source of quiescent myogenic stem cells that can be injected to enhance muscle regeneration. However, the clinical translation of such therapies is hampered by the need for fetal bovine serum (FBS) during the in vitro generation of human MuRCs. This study aimed to determine whether fresh allogeneic human platelet-rich plasma (PRP) combined or not with hyaluronic acid (PRP-HA) could effectively replace xenogeneic FBS for the ex vivo expansion and differentiation of human primary myoblasts. Cells were cultured in media supplemented with either PRP or PRP-HA and their proliferation rate, cytotoxicity and myogenic differentiation potential were compared with those cultured in media supplemented with FBS. The results showed similar proliferation rates among human myoblasts cultured in PRP, PRP-HA or FBS supplemented media, with no cytotoxic effects. Human myoblasts cultured in PRP or PRP-HA showed reduced fusion ability upon differentiation. Nevertheless, we also observed that human MuRCs generated from PRP or PRP-HA myogenic cultures, exhibited increased Pax7 expression and delayed re-entry into the cell cycle upon reactivation, indicating a deeper quiescent state of human MuRCs. These results suggest that allogeneic human PRP effectively replaces FBS for the ex vivo expansion and differentiation of human myoblasts and favors the in vitro generation of Pax7 High human MuRCs, with important implications for the advancement of stem cell-based muscle repair strategies.
Keyphrases
- endothelial cells
- stem cells
- platelet rich plasma
- skeletal muscle
- induced pluripotent stem cells
- pluripotent stem cells
- cell cycle
- cell therapy
- type diabetes
- insulin resistance
- adipose tissue
- low dose
- oxidative stress
- risk assessment
- mesenchymal stem cells
- poor prognosis
- induced apoptosis
- metabolic syndrome
- cell cycle arrest
- climate change